LENZ THERAPEUTICS INC (LENZ) Stock News

USA - Nasdaq - NASDAQ:LENZ - US52635N1037 - Common Stock

30 USD

-0.52 (-1.7%)

Last: 12/1/2025, 9:45:23 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LENZ Latest News, Press Relases and Analysis

All

Press Releases

2 hours ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

2 hours ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

6 days ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Present at Upcoming Investor Conferences

6 days ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Present at Upcoming Investor Conferences

26 days ago - By: Benzinga - Mentions: AMGN GILD TEVA PFE ...

10 Health Care Stocks Whale Activity In Today's Session

a month ago - By: Zacks Investment Research - Mentions: ROIV

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

a month ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

a month ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

a month ago - By: Zacks Investment Research

LENZ Therapeutics, Inc. (LENZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

a month ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

2 months ago - By: LENZ Therapeutics

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

2 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

2 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

3 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

4 months ago - By: The Motley Fool

Lenz (LENZ) Q2 Revenue Jumps 604%

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

4 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

5 months ago - By: Zacks Investment Research

LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?

5 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

6 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Present at Upcoming Investor Conferences

7 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

7 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

7 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

7 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

7 months ago - By: LENZ Therapeutics, Inc.

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference